2009年-普华永道全球_Pharma_2020_Marketing_the_future_-_Which_path_will_you_take__32页_943kb

Pharma 2020: Marketing the Future – Summary

Core Content

The document "Pharma 2020: Marketing the future Which path will you take?" outlines the evolving landscape of pharmaceutical marketing and sales in the context of significant changes in the healthcare industry. It emphasizes the need for pharmaceutical companies to adapt their strategies to meet the new expectations of healthcare stakeholders, including policy-makers, payers, providers, and patients.

Main Trends and Challenges

The pharmaceutical industry is facing several major trends and challenges that will shape its future:

• Chronic Disease Burden: The prevalence of chronic diseases is increasing due to aging populations and lifestyle changes, leading to a greater need for long-term treatment solutions.
• Healthcare Policy Influence: Healthcare payers and policy-makers are increasingly involved in determining the value and pricing of medicines, which affects how Pharma markets its products.
• Pay-for-Performance: There is a growing trend towards pay-for-performance models, where reimbursement is tied to the outcomes of treatments, requiring Pharma to demonstrate the real-world effectiveness of its products.
• E-Prescribing: The adoption of e-prescribing systems is enabling payers to influence prescribing decisions more directly, which shifts power away from Pharma and toward healthcare providers and payers.
• Direct-to-Consumer (DTC) Advertising: While DTC advertising was once a powerful tool, its effectiveness is diminishing, and it faces increasing regulatory scrutiny.
• Patient Empowerment: Patients are becoming more informed and involved in healthcare decisions, especially with the rise of Health 2.0 and online health resources.
• Global Market Variability: The pharmaceutical industry must adapt its strategies to the diverse needs of developing and developed markets, including different regulatory environments and healthcare systems.
• Cost-Cutting and Workforce Reduction: Pharma companies are reducing their sales and marketing staff due to declining effectiveness of traditional marketing methods and increasing pressure to be more efficient.

Key Assumptions and Their Invalidations

The document identifies three incorrect assumptions that have shaped the current marketing and sales model:

1. Pharma Alone Determines Product Value: The value of medicines is now influenced by multiple stakeholders, including healthcare payers and patients.
2. Products Alone Create Value: Value is increasingly derived from the combination of products and services, not just the product itself.
3. Pricing Based Solely on Technical Data: Pricing decisions are now more influenced by subjective criteria, such as quality of life, than just clinical data like safety and efficacy.

Strategic Recommendations

To navigate the changing healthcare landscape, the document recommends the following strategic shifts for pharmaceutical companies:

• Recognize Interdependence: Understand the interdependence between the pharmaceutical, payer, and provider value chains to improve collaboration and efficiency.
• Invest in Market-Driven Medicines: Focus on developing medicines that align with the needs and preferences of the market.
• Form Alliances: Build a web of alliances to offer comprehensive support services beyond just products.
• Plan for Specialist Therapies: Develop detailed marketing and sales plans for specialist therapies that address specific patient needs.
• Create Suitable Organizational Cultures: Foster cultures that support the marketing of complex healthcare packages.
• Manage Multi-Country Launches: Develop strategies for managing launches and licensing across different countries.
• Adopt Flexible Pricing Models: Move towards more flexible pricing strategies that reflect the performance and outcomes of medicines.
• Build Future-Ready Marketing Functions: Rebuild marketing and sales functions to be more effective in the new healthcare environment.

Conclusion

The document concludes that the pharmaceutical industry must move away from traditional aggressive marketing approaches and instead focus on creating a more integrated, patient-centric, and outcome-driven model. This transformation is essential for maintaining value in an increasingly regulated and informed healthcare market.